Home / Motor Neurone Disease

Maylake Pty Ltd is proud to sponsor and support the MND Gold Coast Support Group

The MND Gold Coast Support Group hold their Bi-monthly support Group meeting on the 2nd Saturday of every second month from 1:00pm to 3:00pm

The MND Gold Coast Support Group invite you to join them in a friendly relaxed atmosphere for a coffee and a chat, family and friends are more than welcome.

Please join us for a complimentary afternoon tea or coffee no booking or rsvp necessary

Venue:

Gold Coast Business Hub
Level 2 “Kay House”
35-39 Scarborough Street
Southport Qld 4215

Meeting Dates for 2020 - Times 1pm to 3pm :   8th February  - 11th April -  13th June  -  8th August  -  10th October  -  12th December 

What is Motor Neurone Disease (MND)?

Motor Neurone Disease is the name used to describe a group of diseases in which the nerve cells (neurones) in the brain and spinal cord that control the way we walk, talk, eat, swallow, and breathe progressively die. In some countries, MND is known as Amyotrophic Lateral Sclerosis (ALS), and in the US, it is also called Lou Gehrig’s disease.

Some of The facts:

  • MND is a progressive neurodegenerative disease
  • There is no cure for MND
  • MND can affect anyone at any stage of their lives
  • There are ~2000 people currently affected by MND in Australia (60% male, 40% female)3
  • Everyday in Australia, 2 people are diagnosed with MND, and 2 people die from MND
  • The estimated lifetime risk for MND is 1:3004
  • About 10% of cases run in the family, the remaining 90% of cases have no known genetic link
  • The total economic cost of MND in Australia was $2.37 billion in 2015, which equates to $1.1 million per person3

Refs:

2.Ferrari, R. et al. FTD and ALS: a tale of two diseases. Curr Alzheimer Res. 2011 May; 8(3): 273–294.

3.Kiernan M.C., et al., 2011. Amyotrophic lateral sclerosis. Lancet. 377 (9769): 942–955.

4.Deloitte Access Economics report: Economic Analysis of MND in Australia 2015 report for Motor Neurone Disease Australia, Deloitte Access Economics, Canberra, November.

5.Factor-Litvak et al. Current pathways for epidemiological research in amyotrophic lateral sclerosisALS FTD 2013; 14 (Suppl. 1): 33–43.

For further information please contact

MND Queensland http://www.mndaq.org.au/Home.aspx

MND and Me Foundation http://www.mndandme.com.au/

MND Australia http://www.mndaust.asn.au/Home.aspx